Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer (PLUMMB)
Phase I Study of Hypofractionated Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) in the Treatment of Advanced Bladder Cancer
Sponsor: Institute of Cancer Research, United Kingdom
A PHASE1 clinical study on Invasive Bladder Cancer, this trial is ongoing. The trial is conducted by Institute of Cancer Research, United Kingdom and has accumulated 12 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1
Status: Unknown → Active Not Recruiting
-
Sep 2024 — Feb 2026 [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Recruiting → Unknown
-
Jun 2022 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2021 — Jun 2022 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
▶ Show 7 earlier versions
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE1
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2019 — May 2020 [monthly]
Recruiting PHASE1
-
Jul 2019 — Sep 2019 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Jun 2018 — Jul 2019 [monthly]
Suspended PHASE1
-
May 2018 — Jun 2018 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jan 2017 — May 2018 [monthly]
Recruiting PHASE1
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institute of Cancer Research, United Kingdom
- Merck Sharp & Dohme LLC
- National Institute for Health Research, United Kingdom
- Royal Marsden NHS Foundation Trust
For direct contact, visit the study record on ClinicalTrials.gov .